Phase 3 Trial Results Show Personalized mRNA Vaccine Intismeran Autogene Significantly Reduces Risk of Skin Cancer Recurrence
In a major milestone for clinical oncology, researchers from Moderna and Merck published positive results from the Phase 3 trial of intismeran autogene, the world’s first custom-designed mRNA cancer vaccine.
Published September 8, 2026
CAMBRIDGE, Mass. & RAHWAY, N.J. — Researchers have announced groundbreaking Phase 3 clinical trial data for intismeran autogene, marking the first time an individualized mRNA cancer vaccine has successfully achieved Phase 3 efficacy milestones in oncology.
Unlike traditional vaccines aimed at preventing infectious diseases, intismeran autogene is a personalized therapeutic vaccine. The treatment is manufactured individually for each patient: scientists biopsy the patient's surgical tumor tissue, sequence its unique mutational profile, and select specific neoantigens most likely to trigger an immune response. The custom mRNA strand is then formulated into a vaccine that teaches the patient's T-cells to identify and eliminate microscopic remaining tumor cells.
In the landmark global trial involving high-risk melanoma patients, the combination of intismeran autogene and anti-PD-1 immunotherapy delivered a statistically significant reduction in disease recurrence or death compared to standard immunotherapy alone.
Oncologists and medical researchers emphasize that this success validates mRNA biotechnology as a viable platform for personalizing therapeutic cancer care. Phase 3 trials investigating similar personalized mRNA protocols for lung, pancreatic, and colorectal cancers are currently underway across major academic medical centers in North America.